skip to content


16:40 on 24/11/2017

Current Price 100.50p | Bid 98.75p | Ask 100.50p | Change 1.90%

Company Overview

ImmuPharma PLC (formerly General Industries PLC) is a drug discovery and development company headquartered in London, UK. It has research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases characterised by: blockbuster potential in niche markets; very high margin; low promotional costs in few specialised physicians and centres and lower risk of drug development and lower development costs. ImmuPharma is a currently developing drug candidates for three different medical conditions, each of which would represent a significant breakthrough in its field. The furthest advanced drug candidate targets Lupus, a disease for which there is currently no cure or specific treatment. The other two address moderate to severe pain (such as that experienced by cancer sufferers and post-operative patients), and MRSA and similar severe hospital-acquired resistant infections. All three have significant sales potential as well as low marketing costs and a relatively low risk of development failure. One or more have the potential to be fast-tracked by the US Food and Drug Administration according to 'Guidance for Industry: Fast Track Drug Development Programs - Designation, Development and Application Review' issued July 2004 and could therefore obtain their market authorization by 2010. Key to the potential success of ImmuPharma is its unique collaborative agreement with Centre National de la Recherche Scientifique, France's scientific research institution. This agreement grants ImmuPharma worldwide exclusive rights to exploit certain key discoveries. In addition to its three leading drug candidates, ImmuPharma has a drug development pipeline using its rights to a virtual chemical library of hundreds of thousands of molecules as well as an innovative technology for converting peptides to drug candidates.

Stock Details

ISIN GB0033711010
Shares in Issue 121,781,219
Market cap £ 45.06m
Sector Pharmaceuticals & Biotechnology
Indices FTSE AIM All-Share Index

Key Personnel

Richard Warr Chairman
Dimitri Dimitriou CEO

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Price Summary

Mid Price ? 100.50p
Bid Price ? 98.75p
Ask Price ? 100.50p
Volume ? 118192
Change Today 1.88p
% Change Today 1.90%
Open 97.95p
Previous Close 100.50p
Intraday High 100.50p
Intraday Low 97.95p
52 Week High 48.25p
52 Week Low 19.75p

Intra-Day Chart

More Charts »

Broker Consensus

The above information represents a selection of the views and target prices published in the last 120 days by analysts in individual stocks. It is subject to change without notice and may not necessarily be the view held by Redmayne-Bentley.

Client Area Access

» Secure Login

» Not registered yet?

Sabre Aberdeen Ediston

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.